GlassScriptPhysician profile
Pedro Sepulveda
NPI 1407931108
$10,007.59
in general payments reported to CMS, 2019-2025
34 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $1,381 · 2021: $1,978 · 2022: $1,464 · 2023: $1,658 · 2024: $1,432 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,028 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.80 |
| Education | $123.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,493.60 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,256.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,002.16 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $448.91 | 2019-2023 | Opsumit, Uptravi |
| Insmed, INC. | $446.07 | 2023-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $369.53 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $289.02 | 2019-2025 | Dupixent |
| Philips North America LLC | $223.39 | 2020-2024 | (Ak6) Vest Therapy |
| United Therapeutics Corporation | $159.81 | 2021-2024 | Tyvaso |
| Baxter Healthcare | $155.97 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $146.19 | 2022-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Takeda Pharmaceuticals U.S.A., INC. | $131.82 | 2021-2025 | Glassia |
| Genzyme Corporation | $105.46 | 2019-2020 | |
| Advanced Respiratory, INC | $92.92 | 2020-2021 | |
| Lilly USA, LLC | $88.78 | 2025 | Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.19 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $71.74 | 2020 | |
| Fisher & Paykel Healthcare INC | $62.75 | 2021-2024 | Fisher & Paykel Healthcare |
| Grifols USA, LLC | $39.59 | 2020 | |
| Mallinckrodt Hospital Products INC. | $38.27 | 2024 | Acthar |
| Amgen INC. | $34.00 | 2025 | |
| Verona Pharma, INC. | $33.27 | 2025 | Ohtuvayre |
| Circassia INC. | $31.89 | 2019 | |
| Itamar Medical INC | $30.90 | 2023 | Watchpatone |
| Alk-Abello, INC | $26.11 | 2023 | Ragwitek, Odactra, Grastek |
| Astellas Pharma US INC | $22.69 | 2024 | Cresemba |
| Csl Behring | $18.75 | 2019 | |
| 3b Medical, INC. | $18.24 | 2024 | Luna |
| Harmony Biosciences LLC | $17.67 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.07 | 2021 | |
| Shire North American Group INC | $16.46 | 2019 | |
| Inspire Medical Systems, INC. | $13.55 | 2025 | Inspire |
| Genentech USA, INC. | $11.99 | 2019 | |
| Gilead Sciences, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Sepulveda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.